
    
      Patients are randomized to receive either thalidomide at 1 of 2 doses or placebo for 8 weeks.
      Patients who respond may continue in double-blinded treatment for an additional 4 weeks;
      nonresponding patients may receive thalidomide for up to 4 weeks. Per amendment, patients may
      receive thalidomide for more than 12 weeks on a compassionate basis.
    
  